Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Leigh D Church1, Sinisa Savic2, Michael F McDermott21Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, The University of Birmingham, Birmingham, UK; 2Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Wellcome Tru...
Guardado en:
Autores principales: | Leigh D Church, Sinisa Savic, Michael F McDermott |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7c1d1dc2c87d46f3a90f0e2b1d4596ab |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Justin Gillespie, et al.
Publicado: (2010) -
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Ori Toker, et al.
Publicado: (2010) -
Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Pierre Quartier
Publicado: (2011) -
Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
por: Kawai M, et al.
Publicado: (2013) -
Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin- associated periodic syndromes
por: Bachove I, et al.
Publicado: (2014)